Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Ask the Experts: 3D Cell Culture and Assays

This webinar will answer:

  • What are the different types of 3D models?
  • How can I evaluate cell-based assays for use in 3D cultures?
  • What assays are optimized for 3D?

Summary

3D culture models have many benefits compared to 2D models, including increased physiological relevance and better prediction of in vivo responses to drug treatments. But most existing cell-based assays are designed for 2D cultures and may not produce the same results in 3D cultures. Thus, it is important to understand how 3D structures might impact assay performance and to ensure the assay is optimized for 3D models.

Join this webinar as 3D culture experts from Corning and Promega answer questions about common methods to form 3D structures, and factors to consider when evaluating cell-based assays for use with 3D structures. Learn about the novel viability and cytotoxicity assays that do not lyse cells and allow for additional multiplexing with nucleic acid purification or other markers of cell function. 


Speakers

terry-riss-125x126

Terry Riss, PhD
Senior Product Manager, Cell Health
Promega Corporation

Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and held several R&D and Project Management positions since. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death.  Dr. Riss now serves as Senior Product Manager, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models. Dr. Riss also serves as an editor of the In Vitro Cell-Based Assays section of the Assay Guidance Manual hosted by The National Center for Advancing Translational Sciences (NCATS) at the NIH.

headshot-mogen-125x126

Austin Mogen, PhD
Field Application Scientist
Corning Life Sciences

Dr. Austin Mogen is a Field Application Scientist at Corning Life Sciences. He received his doctorate from the University of Florida and gained industry experience as both a Senior Scientist of upstream process development and Supervisor for manufacturing of viral vectors. In this position he focused on bioprocess development, closed system solutions for cell culture scale-up, and production of viral vectors for cell and gene therapy. Dr. Mogen works extensively with academic researchers and process development groups, optimizing cell culture assays and cellular scale-up conditions. In addition, he focuses on collaborations utilizing high-end 3D technology products such as the Corning spheroid microplates, transwell inserts, and extracellular matrices to provide more in vivo models for biological research and therapeutic response.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up